SMS Pharmaceuticals has received establishment inspection report (EIR) for its Bachupally facility in Hyderabad, from the US health regulator.
The company in a regulatory filing stated that, the company’s manufacturing facility at Bachupally, Hyderabad, has got EIR from the United States Food and Drug Administration (USFDA).
SMS Pharmaceuticals further added, “The facility was inspected by the USFDA in November, 2017 and there were no Form 483 observations during the inspection.”
Furthermore,as per USFDA, an EIR is issued to a company after the successful completion of its facility’s inspection, detailing inspectional findings.
